Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Jaguar Health, Inc. | a17-27133_1ex99d2.htm |
| EX-99.1 - EX-99.1 - Jaguar Health, Inc. | a17-27133_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2017
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36714 |
|
46-2956775 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
201 Mission Street, Suite 2375 |
|
94105 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 2.02 Results of Operations and Financial Conditions.
On November 14, 2017, Jaguar Health, Inc. (“Jaguar” or the “Company”) issued a press release announcing third quarter 2017 results, year-to-date sales of Mytesi® (crofelemer), the first-in-class, FDA-approved anti-secretory human prescription drug product of Jaguar’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), and a company update. The Company also conducted a conference call on November 14, 2017, during which members of its senior management team discussed these same topics. Copies of the press release and the relevant excerpt from the transcript of the conference call are furnished as Exhibits 99.1 and 99.2, respectively, to this report.
The information in this Form 8-K and the exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
|
|
|
99.2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
JAGUAR HEALTH, INC. | ||
|
|
| ||
|
|
|
| |
|
|
By: |
/s/ Karen S. Wright | |
|
|
|
Name: |
Karen S. Wright |
|
|
|
Title: |
Chief Financial Officer |
Date: November 14, 2017